Prevent cancer preclinical drug development program: toxicology and pharmacology testing
Active Awarded Last action
- Contract number
- 75N91024D00001
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5 Part of Illinois Institute Of Technology
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Prevent IDIQ mato RFP Pre-Solicitation · 75N91023R00024 · Posted Dec 19, 2022
- Last date to order 55% complete
- IDV ceiling
- $149,995,000.00
- Maximum order
- $149,995,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 9 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a multiple-award indefinite-delivery contract to IIT Research Institute on January 25, 2024, with a ceiling of $149.995 million and an ultimate completion date of January 24, 2029, for the PREVENT Cancer Preclinical Drug Development Program: Toxicology and Pharmacology Testing.
The IDIQ covers preclinical efficacy evaluation, analytical testing, process development, and toxicological testing of cancer preventive agents. IIT Research Institute is a nonprofit contract research organization and wholly-owned subsidiary of Illinois Institute of Technology, based in Chicago, Illinois. The contract carries no set-aside designation.
Recent delivery orders under this IDIQ include a $1.89 million cost-plus-fixed-fee order for toxicology studies in rats and dogs administered the experimental compound AIT-102, awarded September 16, 2024. The National Cancer Institute dominates IIT Research Institute's federal customer base by potential value, with 50 awards worth $663.1 million combined across all vehicles, though this IDIQ represents one ordering vehicle within that broader relationship.
Performance is conducted at IIT Research Institute's facilities in Chicago. The organization conducts Good Laboratory Practice and non-GLP toxicology studies in rodent and canine models, dose range-finding evaluations, pharmacokinetic analyses, safety assessments, and efficacy evaluations for small molecule and biologic drug candidates. IIT Research Institute delivers preclinical research services through direct employment rather than subcontractor routing.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91024D00001?
75N91024D00001 was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on January 25, 2024.
How much is contract 75N91024D00001 worth?
75N91024D00001's own ceiling is $149,995,000. A single order can be worth up to $149,995,000.
Who can order from contract 75N91024D00001?
75N91024D00001 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N91024D00001 part of a contract vehicle?
Yes. 75N91024D00001 is part of PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024D00001 competed?
The extent of competition for 75N91024D00001 was full and open competition. The government received 9 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV